Cannabis Law Report

MARCH 3, 2020

In Indianapolis on January 29, a quiet, eager audience of nurses give their rapt attention to Jason Straw as he takes center stage at the 2020 ISNA Policy Conference. ISNA 2020 POLICY CONFERENCE AGENDA, Jason Straw- Cannabis Policy. ISNA 2020 POLICY CONFERENCE AGENDA, Jason Straw- Cannabis Policy. PURPOSE : .

Policy 105

Policy Research and Development Chronic Pain Cannabinoids 105

Cannabis Law Report

NOVEMBER 22, 2021

Thailand’s Public Health Ministry has signed a Memorandum of Understanding (MOU) with RxLeaf World Medica on establishing the International Medical Cannabis Research Center. The latest movement is a part of Thailand’s plan to be a world-class cannabis production and development hub. For more information [link].

Research and Development 52

Research and Development Epilepsy Cannabis Food 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Opportunities for Federal Support of Psychedelics Research. Background. The Project.

Law 59

Law Policy Research and Development Clinical Trials 59

Illinois News Joint

APRIL 27, 2024

Professors and professionals in the cannabis field will deliver research and educational presentations from 12:30-4:20 p.m. Presenters include representatives from Southern Illinois University, Female Orgasm Research Institute, St. at the Garden Grove Event Center in Carbondale on May 4. 3:30 p.m. – 3:30 p.m. – Marialle A. 2:00 p.m. –

Research and Development 74

Research and Development Events Environment Education 74

Veriheal

FEBRUARY 14, 2024

The vote passed 7-0 after a group of senators, first responders, and military members held a press conference regarding the benefits and potential of psilocybin, also known as magic mushrooms , for mental health treatment. This will also include licensing for centers that are working on psilocybin and psychedelic research.

Therapy 62

Therapy Legalization Research and Development Treatment 62

MMJ Recs

FEBRUARY 10, 2024

Scientific research, patient testimonials, and a broader understanding of the plant’s medicinal properties have fundamentally altered public views. This change is driven by a combination of scientific research, increased education, and a desire for alternative healthcare options.

Research and Development 105

Research and Development Marijuana History Legislation 105

Cannabis Law Report

SEPTEMBER 22, 2021

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

PrestoDoctor

JANUARY 30, 2024

By exploring the signs and symptoms, risk factors, mechanism of action, and treatment options for cannabis-induced psychosis, we can better equip ourselves with the knowledge needed to prevent and manage this condition. Studies have shown that individuals who use cannabis are at an increased risk of developing psychotic symptoms.

Research and Development 52

Research and Development Treatment Conditions Education 52

Cannabis Law Report

APRIL 19, 2023

Here’s the blurb With research showing that psychedelics hold substantial promise for the treatment of mental health conditions such as depression, PTSD and addiction, PSYCH Symposium provides a platform for decision makers to accelerate the development and delivery of these medicines.

Research and Development 52

Research and Development Events Treatment Policy 52

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. Policy decisions related to taxation, zoning, and advertising also impact the industry’s operations and growth trajectory.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

JUNE 25, 2021

Nutt Will Drive Progression of a Pipeline of New Psychedelic Medicines, Helping to Define a Clear Development Pathway to Treat Addiction Through Psychedelic Medicines. David Nutt, has joined its executive team as Chief Research Officer. Toronto, Ontario–(Newsfile Corp. June 24, 2021) – Awakn Life Sciences Corp.

Research and Development 66

Research and Development Therapy Medicine Pets 66

Cannabis Law Report

JUNE 19, 2022

The Center for Psychedelic Drug Research and Education (CPDRE) was approved by the Ohio State College of Social Work faculty in January, and its director, Assistant Professor of Social Work Alan Davis , officially took the helm in March. Initial goals of the center are focused on research and educational initiatives.

Education 52

Education Research and Development Therapy Clinical Trials 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

The Cannigma

MARCH 2, 2021

This issue is compounded when veterans do, on rare occasions, ask their doctors about medical marijuana, only to be treated as if they are mentally unstable or receive no specific health information at all,” the researchers found. This directly conflicts with past research claiming marijuana increases PTSD symptom severity.”.

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JULY 19, 2021

Philip Morris International recently offered £1 billion to buy Vectura Group PLC, the British pharmaceutical company that develops inhaled medical products. The post RYAH Group Partners with the University of Milan to Develop Conversion Measurement Standards for Dry Herb Inhalation Therapies appeared first on CannabisFN.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

AUGUST 3, 2022

The lack of robust research on cannabis products, cannabis as a therapy and dependence or addiction to cannabis heightens the challenge of developing sound policies on the use of cannabis in health care facilities. Food and Drug Administration.

Research and Development 98

Research and Development Policy Patients Compliance 98

Cannabis Law Report

SEPTEMBER 9, 2021

The current public policies in local and state cannabis ordinance and equity programs may enhance racial disparities if they follow the pattern of exclusion and criminalization that encompass past policies promoted as beneficial to African Americans but uphold racial capitalistic practices. Central Research Question.

Policy 105

Policy Research and Development Collective Banking 105

MMJ Recs

DECEMBER 22, 2023

Historically, marijuana was vilified and classified as a Schedule I controlled substance, which hindered both research and public acceptance. The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. It prompts considerations regarding patient access, treatment options, and healthcare provider involvement.

Legalization 52

Legalization Access Programs Education 52

MMJ Recs

OCTOBER 26, 2023

Missouri : Missouri has a developing MMJ program, with a list of qualifying conditions and licensed dispensaries. To fully grasp the legal status of medical marijuana, one must consider both state-specific regulations and federal policies. Mississippi: Mississippi has a growing MMJ program, and voters approved its legalization in 2020.

Law 98

Law Marijuana Programs Dispensary 98

Cannabis Law Report

OCTOBER 17, 2019

(Tree of Knowledge) (CSE:TOKI) (OTC:TOKIF) expands global medical marijuana and CBD research in partnership with the Caribbean Institute of Pharmacy Policy (CIPPPAR) in Jamaica. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

MAY 18, 2022

A recent publication in the prominent peer-reviewed journal Nature, shows that 67% of patients no longer qualified for a PTSD diagnosis a year after treatment with MDMA (or “ecstasy”).

Research and Development 52

Research and Development Therapy Treatment Policy 52

The Cannigma

JUNE 2, 2023

The possession, use, and trafficking of cannabis are illegal, and the country maintains a zero-tolerance policy towards drugs. The government emphasizes alternative medical treatments and invests in research and development for non-cannabis-based therapies.

Law 52

Law Research and Development Consumption Therapy 52

Cannabis Law Report

AUGUST 10, 2021

(“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 8, 2021

As the fund works to bring to market psychedelic treatments that are poised to revolutionize the way we treat mental health and addiction issues, Palo Santo has appointed Charles D. These leaders bring an unparalleled depth of experience in psychedelic science, medicine, development, and law. Holland has worked for decades on U.S.

Research and Development 52

Research and Development Medicine Treatment Access 52

United Patients Group

JUNE 26, 2023

They often possess a more profound understanding of healthcare policies, advanced practice procedures, and innovative research methodologies. These comprehensive programs focus on developing skills in patient care, policy interpretation, and research methods.

Research and Development 52

Research and Development Education Patients Policy 52

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

FloridaMarijuana.net

JULY 8, 2018

The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

JANUARY 27, 2022

If passed the bill will establish the “Task Force on Psilocybin Equity” that will research problems relating to access and equity in Oregon’s emerging psilocybin program. The task force will complete a study and provide policy recommendations that will serve as a basis for substantive policy reforms during the 2023 legislative session.

Research and Development 52

Research and Development Policy Access Legislation 52

Cannabis Law Report

JUNE 24, 2022

Scutari’s proposed “Psilocybin Behavioral Health Access and Services Act” represents a bold development in the psychedelics reform movement that’s rapidly spread in state legislatures and through citizen-led initiatives throughout the country in recent years.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

MMJ Recs

MARCH 20, 2024

Many dispensaries also offer additional services such as educational resources, patient consultations, and ongoing support programs to address patient concerns and enhance their overall treatment experience. Maryland continues to embrace innovation and progress in its cannabis industry, positioning itself as a leader in the region.

Dispensary 52

Dispensary Programs Access Patients 52

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development 79

Research and Development Therapy Consumption DEA 79

Cannabis Law Report

MAY 26, 2022

The OPEN Foundation invites you to the Interdisciplinary Conference on Psychedelic Research this September, featuring the world’s best experts on psychedelic science and therapy. Research participant perspectives are featured prominently, and experts will discuss issues around ethics, investment, and the hype surrounding psychedelics.

Research and Development 52

Research and Development Therapy Policy Media 52